{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:21:06Z","timestamp":1790936466382,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1124\/jpet.103.061200","type":"journal-article","created":{"date-parts":[[2004,3,26]],"date-time":"2004-03-26T18:07:46Z","timestamp":1080324466000},"page":"414-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["SSR126768A (4-Chloro-3-[(3 R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2- oxo-2,3-dihydro-1 H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, Hydrochloride): A New Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor"],"prefix":"10.1016","volume":"309","author":[{"given":"Claudine","family":"Serradeil-Le Gal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Valette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Foulon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Advenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Naline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bardou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Martinolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Pouzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Raufaste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u00e9onore","family":"Double-Cazanave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Pauly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pascal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Scatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Maffrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Le Fur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.103.061200_bib1","doi-asserted-by":"crossref","unstructured":"Akerlund M (2002) Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea, in Progress in Brain Research (Poulain D, Oliet S, and Theodosis D eds), vol 139, pp 359-365, Elsevier, Paris, France.","DOI":"10.1016\/S0079-6123(02)39030-7"},{"key":"10.1124\/jpet.103.061200_bib2","doi-asserted-by":"crossref","unstructured":"Akerlund M, Bossmar T, Brouard R, Kostrzewska A, Laudanski T, Lemancewicz A, Serradeil-Le Gal C, and Steinwall M (1999) Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br J Obstet Gynaecol 106: 1047-1053.","DOI":"10.1111\/j.1471-0528.1999.tb08112.x"},{"key":"10.1124\/jpet.103.061200_bib3","doi-asserted-by":"crossref","unstructured":"Akerlund M, Stromberg P, Hauksson A, Andersen LF, Lyndrup J, Trojnar J, and Melin P (1987) Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot study. Br J Obstet Gynaecol 94: 1040-1044.","DOI":"10.1111\/j.1471-0528.1987.tb02287.x"},{"key":"10.1124\/jpet.103.061200_bib4","unstructured":"Allen MJ, Smith J, Hampton S, and Giles H (1997) Affinity of antagonists and endogenous peptides at human recombinant oxytocin and vasopressin receptors, in Word Congress of Neurohypophysial Hormones, Montreal, Canada, August 8-12, A176 (Abstr.)"},{"key":"10.1124\/jpet.103.061200_bib5","doi-asserted-by":"crossref","unstructured":"Arunlakshana O and Schild H (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14: 48-58.","DOI":"10.1111\/j.1476-5381.1959.tb00928.x"},{"key":"10.1124\/jpet.103.061200_bib6","doi-asserted-by":"crossref","unstructured":"Bardou M, Loustalot C, Cortijo J, Simon B, Naline E, Dumas M, Esteve S, Croci T, Chalon P, Frydman R, et al. (2000) Functional, biochemical and molecular biological evidence for a possible beta(3)-adrenoceptor in human near-term myometrium. Br J Pharmacol 130: 1960-1966.","DOI":"10.1038\/sj.bjp.0703491"},{"key":"10.1124\/jpet.103.061200_bib7","doi-asserted-by":"crossref","unstructured":"Bell IM, Erb JM, Friedinger RM, Gallicchio SN, Guare JP, Guidotti MT, Halpin RA, Hobbs DW, Homnick CF, Kuo MS, et al. (1998) Development of orally active oxytocin antagonists: studies on 1-(1-{4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxyl-2-methoxybenzoyl}piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. J Med Chem 41: 2146-2163.","DOI":"10.1021\/jm9800797"},{"key":"10.1124\/jpet.103.061200_bib8","unstructured":"Carbillon L, Seince N, and Uzan M (2001) Myometrial maturation and labour. Ann Med 33: 571-578."},{"key":"10.1124\/jpet.103.061200_bib9","doi-asserted-by":"crossref","unstructured":"Carbonne B, Cabrol D, Clerget MS, and Germain G (1998) Effects of nomegestrol acetate on spontaneous and sulprostone-induced uterine contractions in pregnant cynomolgus monkeys monitored by telemetry. Am J Obstet Gynecol 178: 150-155.","DOI":"10.1016\/S0002-9378(98)70643-X"},{"key":"10.1124\/jpet.103.061200_bib10","doi-asserted-by":"crossref","unstructured":"Chen DL, Chan WY, and Manning M (1994) Agonist and antagonist specificities of decidual prostaglandin-releasing oxytocin receptors and myometrial uterotonic oxytocin receptors in pregnant rats. J Reprod Fertil 102: 337-343.","DOI":"10.1530\/jrf.0.1020337"},{"key":"10.1124\/jpet.103.061200_bib11","doi-asserted-by":"crossref","unstructured":"Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.","DOI":"10.1016\/0006-2952(73)90196-2"},{"key":"10.1124\/jpet.103.061200_bib12","doi-asserted-by":"crossref","unstructured":"Cirillo R, Gillio Tos E, Schwarz MK, Quattropani A, Scheer A, Missotten M, Dorbais J, Nichols A, Borrelli F, Giachetti C, et al. (2003) Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2\u2032-methyl[1,1\u2032-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. J Pharmacol Exp Ther 306: 253-261.","DOI":"10.1124\/jpet.103.049395"},{"key":"10.1124\/jpet.103.061200_bib13","doi-asserted-by":"crossref","unstructured":"Demarest KT, Hahn DW, Ericson E, Capetola RJ, Fuchs AR, and McGuire JL (1989) Profile of an oxytocin antagonist, RWJ 22164 for treatment of preterm labor in laboratory models of uterine contractility. Am J Perinatol 6: 200-204.","DOI":"10.1055\/s-2007-999576"},{"key":"10.1124\/jpet.103.061200_bib14","doi-asserted-by":"crossref","unstructured":"El Alj A, Winer N, Lallaoui H, Delansorne R, Ferre F, and Germain G (1993) Progesterone and mifepristone modify principally the responses of circular myometrium to oxytocin in preparturient rats: comparison with responses to acetylcholine and to calcium. J Pharmacol Exp Ther 265: 1205-1212.","DOI":"10.1016\/S0022-3565(25)38265-0"},{"key":"10.1124\/jpet.103.061200_bib15","doi-asserted-by":"crossref","unstructured":"Elands J, Barberis C, Jard S, Tribollet E, Dreifuss J-J, Bankowski K, Manning M, and Sawyer H (1987) 125I-Labelled d(CH2)5[Tyr(Me)2, Thr4,Tyr-NH29]OVT: a selective oxytocin receptor ligand. Eur J Pharmacol 147: 197-207.","DOI":"10.1016\/0014-2999(88)90778-9"},{"key":"10.1124\/jpet.103.061200_bib16","doi-asserted-by":"crossref","unstructured":"Fuchs AR, Fuchs F, Husslein P, and Soloff MS (1984) Oxytocin receptor in the human uterus during pregnancy and parturitior. Am J Obstet Gynecol 150: 734-741.","DOI":"10.1016\/0002-9378(84)90677-X"},{"key":"10.1124\/jpet.103.061200_bib17","doi-asserted-by":"crossref","unstructured":"Gimpl G and Fahrenholz F (2001) The oxytocin receptor system: structure, function and regulation. Physiol Rev 81: 629-683.","DOI":"10.1152\/physrev.2001.81.2.629"},{"key":"10.1124\/jpet.103.061200_bib18","doi-asserted-by":"crossref","unstructured":"Goodwin TM and Zograbyan A (1998) Oxytocin receptor antagonists. Update. Clin Perinatol 25: 859-871.","DOI":"10.1016\/S0095-5108(18)30087-3"},{"key":"10.1124\/jpet.103.061200_bib19","doi-asserted-by":"crossref","unstructured":"Grynkiewicz G, Poenie M, and Tsien RY (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440-3450.","DOI":"10.1016\/S0021-9258(19)83641-4"},{"key":"10.1124\/jpet.103.061200_bib20","unstructured":"Hall M., Danielian P., and Lamont R. 1997. The Importance of Preterm Birth (Elder M, Lamont R, and Romero R eds) pp 1-28, Churchill Livingstone, New York."},{"key":"10.1124\/jpet.103.061200_bib21","doi-asserted-by":"crossref","unstructured":"Kawamata M, Mitsui-Saito M, Kimura T, Takayanagi Y, Yanagisawa T, and Nishimori K (2003) Vasopressin-induced contraction of uterus is mediated solely by the oxytocin receptor in mice, but not in humans. Eur J Pharmacol 472: 229-234.","DOI":"10.1016\/S0014-2999(03)01914-9"},{"key":"10.1124\/jpet.103.061200_bib22","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Akahane M, Minami K, Moro M, Ajisawa Y, Inoue Y, and Kawarabayashi T (1999) Role of oxytocin in the initiation of term and preterm labor in rats: changes in oxytocin receptor density and plasma oxytocin concentration and the effect of an oxytocin antagonist, L-366,509. Am J Obstet Gynecol 180: 621-627.","DOI":"10.1016\/S0002-9378(99)70264-4"},{"key":"10.1124\/jpet.103.061200_bib23","doi-asserted-by":"crossref","unstructured":"Manning M, Stoev S, Cheng LL, Wo NC, and Chan WY (2001) Design of oxytocin antagonists, which are more selective than atosiban. J Pept Sci 7: 449-465.","DOI":"10.1002\/psc.339"},{"key":"10.1124\/jpet.103.061200_bib24","doi-asserted-by":"crossref","unstructured":"McLean M, Bisits A, Davies J, Woods R, Lowry P, and Smith R (1995) A placental clock controlling the length of human pregnancy. Nat Med 1: 460-463.","DOI":"10.1038\/nm0595-460"},{"key":"10.1124\/jpet.103.061200_bib25","doi-asserted-by":"crossref","unstructured":"McLean M, Walters WA, and Smith R (1993) Prediction and early diagnosis of preterm labor: a critical review. Obstet Gynecol Surv 48: 209-225.","DOI":"10.1097\/00006254-199304000-00001"},{"key":"10.1124\/jpet.103.061200_bib26","doi-asserted-by":"crossref","unstructured":"Mitchell BF and Schmid B (2001) Oxytocin and its receptor in the process of parturition. J Soc Gynecol Investig 8: 122-133.","DOI":"10.1177\/107155760100800302"},{"key":"10.1124\/jpet.103.061200_bib27","doi-asserted-by":"crossref","unstructured":"Nishimori K, Young LJ, Guo Q, Wang Z, Insel TR, and Matzuk MM (1996) Oxytocin is required for nursing but is not essential for parturition or reproductive behavior. Proc Natl Acad Sci USA 93: 11699-11704.","DOI":"10.1073\/pnas.93.21.11699"},{"key":"10.1124\/jpet.103.061200_bib28","doi-asserted-by":"crossref","unstructured":"Pettibone DJ, Kishel MT, Woyden CJ, Clineschmidt BV, Bock MG, Freidinger RM, Veber DF, and Williams PD (1992) Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues. Life Sci 50: 1953-1958.","DOI":"10.1016\/0024-3205(92)90524-S"},{"key":"10.1124\/jpet.103.061200_bib29","doi-asserted-by":"crossref","unstructured":"Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille JC, Tabor B, Perry KG, Varner M, Goodwin TM, Lane R, et al. (2002) An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 182: 1173-1183.","DOI":"10.1067\/mob.2000.95834"},{"key":"10.1124\/jpet.103.061200_bib30","doi-asserted-by":"crossref","unstructured":"Schwarz MK and Page P (2003) Preterm labour: an overview of current and emerging therapeutics. Curr Med Chem 10: 1441-1468.","DOI":"10.2174\/0929867033457331"},{"key":"10.1124\/jpet.103.061200_bib31","doi-asserted-by":"crossref","unstructured":"Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, et al. (1996) Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Investig 98: 2729-2738.","DOI":"10.1172\/JCI119098"},{"key":"10.1124\/jpet.103.061200_bib32","doi-asserted-by":"crossref","unstructured":"Serradeil-Le Gal C, Raufaste D, Double-Cazanave E, Guillon G, Garcia C, Pascal M, and Maffrand JP (2000) Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [3H]-SR121463. Kidney Int 58: 1613-1622.","DOI":"10.1046\/j.1523-1755.2000.00322.x"},{"key":"10.1124\/jpet.103.061200_bib33","doi-asserted-by":"crossref","unstructured":"Serradeil-Le Gal C, Wagnon J, Garcia C, Lacour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, and Le Fur G (1993) Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Investig 92: 224-231.","DOI":"10.1172\/JCI116554"},{"key":"10.1124\/jpet.103.061200_bib34","doi-asserted-by":"crossref","unstructured":"Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G et al (2002) Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl) -2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther 300: 1122-1130.","DOI":"10.1124\/jpet.300.3.1122"},{"key":"10.1124\/jpet.103.061200_bib35","doi-asserted-by":"crossref","unstructured":"Smith R, Mesiano S, and McGrath S (2002) Hormone trajectories leading to human birth. Regul Pept 108: 159-164.","DOI":"10.1016\/S0167-0115(02)00105-2"},{"key":"10.1124\/jpet.103.061200_bib36","doi-asserted-by":"crossref","unstructured":"Sugimoto Y, Yamasaki A, Segi E, Tsuboi K, Aze Y, Nishimura T, Oida H, Yoshida N, Tanaka T, Katsuyama M, et al. (1997) Failure of parturition in mice lacking the prostaglandin F receptor. Science (Wash DC) 277: 681-683.","DOI":"10.1126\/science.277.5326.681"},{"key":"10.1124\/jpet.103.061200_bib37","doi-asserted-by":"crossref","unstructured":"The Worldwide Atosiban versus Beta-Agonists Study Group (2003) Effectiveness and safety of the oxytcin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. Br J Obstet Gynaecol 108: 133-142.","DOI":"10.1111\/j.1471-0528.2001.00043.x"},{"key":"10.1124\/jpet.103.061200_bib38","doi-asserted-by":"crossref","unstructured":"Vatish M and Thornton S (2002) Oxytocin antagonists. Exp Opin Ther Patents 12: 1403-1406.","DOI":"10.1517\/13543776.12.9.1403"},{"key":"10.1124\/jpet.103.061200_bib39","doi-asserted-by":"crossref","unstructured":"Williams PD, Clineschmidt BV, Erb JM, Freidinger RM, Guidotti MT, Lis EV, Pawluczyk JM, Pettibone DJ, Reiss DR, Veber DF, et al. (1995) 1-(1-[4-[(N-Acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4-yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. J Med Chem 38: 4634-4636.","DOI":"10.1021\/jm00023a002"},{"key":"10.1124\/jpet.103.061200_bib40","doi-asserted-by":"crossref","unstructured":"Wilson RJ, Allen MJ, Nandi M, Giles H, and Thornton S (2001) Spontaneous contractions of myometrium from humans, non-human primate and rodents are sensitive to selective oxytocin receptor antagonism in vitro. Br J Obstet Gynaecol 108: 960-966.","DOI":"10.1016\/S0306-5456(01)00226-1"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652431290X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652431290X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.103.061200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:51:11Z","timestamp":1739998271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652431290X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S002235652431290X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.103.061200","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SSR126768A (4-Chloro-3-[(3 R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2- oxo-2,3-dihydro-1 H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, Hydrochloride): A New Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.103.061200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2004 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}